Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity
about
Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantationTherapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic StrategiesEvolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityCurrent and emerging strategies for the prevention of graft-versus-host diseaseCharacterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress ResponsesHsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in miceTherapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice.The triterpenoid CDDO-Me delays murine acute graft-versus-host disease with the preservation of graft-versus-tumor effects after allogeneic bone marrow transplantation.Advances in graft-versus-host disease biology and therapy.Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.Treatment of chronic graft-versus-host disease with bortezomibAllogeneic hematopoietic cell transplantation: the state of the artProteasome inhibitors in the treatment of multiple myelomaTherapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levelsSequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3.The effect of bortezomib on expression of inflammatory cytokines and survival in a murine sepsis model induced by cecal ligation and puncture.Emerging therapies in hematopoietic stem cell transplantationThe synthetic triterpenoid, CDDO, suppresses alloreactive T cell responses and reduces murine early acute graft-versus-host disease mortality.A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantationBone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a reviewStem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents.Proteasome inhibitors: antitumor effects and beyond.Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation.Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantationPharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.Ex vivo inhibition of NF-kappaB signaling in alloreactive T-cells prevents graft-versus-host disease.Combined nifuroxazide and SAT05f therapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.Mouse models of graft-versus-host disease: advances and limitationsThe role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics.Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work.New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade).Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation.
P2860
Q24642254-41EDFEDC-C347-4061-8A5C-CFB43F6A4437Q26751959-602FBB1E-9B18-4D67-90D4-B0565C096D2BQ26771331-A1346BB0-40F7-4A0F-B2D0-C50C752BB40EQ27016541-3071139E-2789-4A42-8F21-05FFD5740DC5Q28271836-6A8BB1BC-56A2-4320-BEC3-E532A79B5BF3Q33707337-1E512786-B368-4A87-8EEE-9A641EA5D6D4Q33792598-A37B50E8-911B-468A-ABAA-59FDF6AC7688Q33838404-08B08325-ED5C-41AD-B3FB-06098A87BE37Q34031916-B03EB989-4058-4BE2-8561-9106977575D9Q34079116-F6F6FBBB-32D8-4513-9DF5-7D871EA35E47Q34137032-2FEC4202-E2DC-492F-A7CB-159C29A1BF8CQ34145155-1D606E5B-1EA5-4A27-8BCC-6455940E3BB5Q34611676-A929FF9A-FF21-4DCD-B37E-E160F322E8E9Q34624143-867BE061-DC6C-4D23-9CB4-C75BF675E3A5Q34703720-AEEFC8F6-E87C-4FE3-977E-F44D1C3820D1Q34774088-39CD8DF4-0DFA-43BB-AD6B-03F22144DC4EQ35825522-FAC6F64E-2DBC-4F36-93D1-B2D59399E2AAQ36024872-DA0EFE79-2D57-4D44-A3F7-0788B710FCEEQ36157163-126706C9-2E07-4642-8EBF-CD0D69BD3EECQ36212400-0D51C3FA-BFBF-44B3-8EE0-A9EEA59F2713Q36251308-18458977-F7C2-4846-BCA1-736D79A9F364Q36408216-B932B732-1361-4BF8-96D6-C2BB9E0C60A4Q36548362-523F61A8-385D-4C06-91B5-6D089447FB6CQ36649676-EFD1FF6A-B172-4F44-A805-22107F9A8D13Q36835147-25503726-9CC6-444A-A486-AE372DDEDEABQ36891433-92C39B8C-2424-4A25-9D24-F9936F72B680Q36980277-BFF2418F-248D-4014-942C-B3A0DBB40FA9Q37186584-C797BA5A-8A7C-49DA-8524-E3FB0A75746BQ37603497-968D36D4-FD93-4D28-B344-BC4A2E5FF990Q37822742-52511E9E-B6C1-4ADB-BFF2-CFDED3BE956CQ37874011-0F504300-7AD9-4DAD-80B1-0240B81B6D7EQ37989141-CBD608DB-ACE7-46A7-BEC5-36211CF5740AQ38029953-0382B281-8B5D-4D2F-AAA7-9A493D3CC533Q38417073-9B6EA5A8-3156-4A51-977E-E17A7EED58A5Q38708402-EAB7EA78-1949-4E05-9837-A9BE4821102AQ39174731-9AD8F238-F845-48F8-B8D0-7D396172EF68Q39307476-25452893-AFE9-4A4E-AE89-EB31244BC18CQ39883372-B6066E50-E03B-4AB7-A57C-B26B4B551360Q39937379-7BFA749F-7117-46A4-80CB-D14F2587AAD0Q41031184-272022FA-C086-419C-AB94-4982209ED843
P2860
Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Differential effects of protea ...... dent gastrointestinal toxicity
@ast
Differential effects of protea ...... dent gastrointestinal toxicity
@en
type
label
Differential effects of protea ...... dent gastrointestinal toxicity
@ast
Differential effects of protea ...... dent gastrointestinal toxicity
@en
prefLabel
Differential effects of protea ...... dent gastrointestinal toxicity
@ast
Differential effects of protea ...... dent gastrointestinal toxicity
@en
P2093
P2860
P1433
P1476
Differential effects of protea ...... dent gastrointestinal toxicity
@en
P2093
Danice E C Wilkins
Lisbeth A Welniak
Miriam R Anver
Thomas J Sayers
William J Murphy
P2860
P304
P356
10.1182/BLOOD-2004-11-4526
P407
P577
2005-06-16T00:00:00Z